Vishnu Priyan

The US FDA has granted fast track designation for iECURE’s ECUR-506 for the treatment of neonatal onset ornithine transcarbamylase deficiency.

Neurogene has shared initial results from its ongoing Phase I/II clinical trial of NGN-401, a gene therapy candidate for Rett syndrome.

Pfizer has reported the death of a patient in the Phase II study of fordadistrogene movaparvovec, to treat Duchenne muscular dystrophy.

The company may make upfront, development, and commercial milestone payments of $600m.

Merck has announced that the Phase III trial of KEYTRUDA regimen in high-risk endometrial cancer patients failed to meet primary endpoint.

Goldman Sachs Alternatives spearheaded the company's Series B financing round.

Kite and Arcellx have announced plans to commence a Phase III trial of anito-cel for treating multiple myeloma.

Maze is entitled to receive $150m in upfront payment from Shionogi.

Tabuk obatined rights to commercialise Formosacs l'obetasol propionate ophthalmic suspension 0.05% for inflammation after ocular surgery.

Fusion Pharmaceuticals dosed the first subject in the Phase II segment of Phase II/III AlphaBreak trial of FPI-2265 to treat prostate cancer.